The gefitinib-sensitizing mutant Epidermal Growth Factor Receptor enables transformation of a mouse fibroblast cell line

DNA and Cell Biology

Volumn 25, Issue 4, 2006, Pages 246-251

  Nagatomo, Izumi ^a   Kumagai, Toru ^a   Yamadori, Tadahiro ^a   Furukawa, Mitsugi ^a   Takahashi, Ryo ^a   Yoneda, Tsutomu ^a   Ogata, Yoshitaka ^a   Saito, Yoshiyuki ^a   Inoue, Koji ^a   Yano, Yukihiro ^a   Kijima, Takashi ^a   Yoshida, Mitsuhiro ^a   Osaki, Tadashi ^a   Tachibana, Isao ^a   Greene, Mark I ^b   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL LINE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA; ENZYME ACTIVATION; FIBROBLASTS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION;

ANIMALIA; MURINAE;

EID: 33646364794     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.246     Document Type: Article

References (33)

1. AMANN, J., KALYANKRISHNA, S., MASSION, P.P., OHM, J.E., GIRARD, L., SHIGEMATSU, H., PEYTON, M., JUROSKE, D., HUANG, Y., SALMON, J.S., et al. (2005). Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65, 226-235.
2. ARAO, T., FUKUMOTO, H., TAKEDA, M., TAMURA, T., SAIJO, N., and NISHIO, K. (2004). Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 64, 9101-9104.
3. BOERNER, J.L., DANIELSEN, A., and MAIHLE, N.J. (2003). Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp. Cell Res. 284, 111-121.
4. DI FIORE, P.P., PIERCE, J.H., FLEMING, T.P., HAZAN, R., ULLRICH, A., KING, C.R., SCHLESSINGER, J., and AARONSON, S.A. (1987). Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51, 1063-1070.
5. ENGELMAN, J.A., JANNE, P.A., MERMEL, C., PEARLBERG, J., MUKOHARA, T., FLEET, C., CICHOWSKI, K., JOHNSON, B.E., and CANTLEY, L.C. (2005). Erb-B3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102, 3788-3793.
6. FUKUOKA, M., YANO, S., GIACCONEi, G., TAMURA, T., NAKAGAWA, K., DOUILLARD, J.Y., NISHIWAKI, Y., VANSTEENKISTE, J., KUDOH, S., RISCHIN, D., et al. (2003). Multi-institutional randomised phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21, 2237-2246.
7. GREULICH, H., CHEN, T.H., FENG, W., JANNE, P.A., ALVAREZ, J.V., ZAPPATERRA, M., BULMER, S.E., FRANK, D.A., HAHN, W.C., SELLERS, W.R., et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313.
8. HAHN, W.C., and WEINBERG, R.A. (2002). Rules for making human tumor cells. N. Engl. J. Med. 347, 1593-1603.
9. HIRSCH, F.R., SCAGLIOTTI, G.V., LANGER, C.J., VARELLA-GARCIA, M., and FRANKLIN, W.A. (2003). Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies. Lung Cancer 41, S29-S42.
10. JORISSEN, R.N., WALKER, F., POULIOT, N., GARRETT, T.P., WARD, C.W., and BURGESS, A.W. (2003). Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 284, 31-53.
11. KOKAI, Y., MYERS, J.N., WADA, T., BROWN, V.I., LEVEA, C.M., DAVIS, J.G., DOBASHI, K., and GREENE, M.I. (1989). Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58, 287-292.
12. KOSAKA, T., YATABE, Y., ENDOH, H., KUWANO, H., TAKAHASHI, T., and MITSUDOMI, T. (2004). Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 64, 8919-8923.
13. neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling. Proc. Natl. Acad. Sci. USA 98, 5526-5531.
14. LEARN, C.A., HARTZELL, T.L., WIKSTRAND, C.J., ARCHER, G.E., RICH, J.N., FRIEDMAN, A.H., FRIEDMAN, H.S., BIGNER, D.D., and SAMPSON, J.H. (2004). Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin. Cancer Res. 10, 3216-3224.
15. LYNCH, T.J., BELL, D.W., SORDELLA, R., GURUBHAGAVATULA, S., OKIMOTO, R.A., BRANNIGAN, B.W., HARRIS, P.L., HASERLAT, S.M., SUPKO, J.G., HALUSKA, F.G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
16. MOSCATELLO, D.K., MONTGOMERY, R.B., SUNDARESHAN, P., MCDANEL, H., WONG, M.Y., and WONG, A.J. (1996). Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13, 85-96.
17. NICHOLSON, R.I., GEE, J.M., and HARPER, M.E. (2001). EGFR and cancer prognosis. Eur. J. Cancer 37, S9-S15
18. OKAMOTO, I., KENYON, L.C., EMLET, D.R., MORI, T., SASAKI, J., HIROSAKO, S., ICHIKAWA, Y., KISHI, H., GODWIN, A.K., YOSHIOKA, M., et al. (2003). Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci. 94, 50-56.
19. OLAYIOYE, M.A., NEVE, R.M., LANE, H.A., and HYNES, N.E. (2000). The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167.
20. O'ROURKE, D.M., NUTE, E.J., DAVIS, J.G., WU, C., LEE, A., MURALI, R., ZHANG, H.T., QIAN, X., KAO, C.C., and GREENE, M.I. (1998). Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly. Oncogene 16, 1197-1207.
21. PAEZ, J.G., JANNE, P.A., LEE, J.C., TRACY, S., GREULICH, H., GABRIEL, S., HERMAN, P., KAYE, F.J., LINDEMAN, N., BOGGON, T.J., et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
22. PAGES, G., LENORMAND, P., L'ALLEMAIN, G., CHAMBARD, J.C., MELOCHE, S., and POUYSSEGUR, J. (1993). Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. USA 90, 8319-8323.
23. PAO, W., MILLER, V., ZAKOWSKI, M., DOHERTY, J., POLITI, K., SARKARIA, I., SINGH, B., HEELAN, R., RUSCH, V., FULTON, L., et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311.
24. PRUSS, R.M., and HERSCHMAN, H.R. (1977). Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc. Natl. Acad. Sci. USA 74, 3918-3921.
25. SAKAI, K., ARAO, T., SHIMOYAMA, T., MUROFUSHI, K., SEKIJIMA, M., KAJI, N., TAMURA, T., SAIJO, N., and NISHIO, K. (2006). Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. FASEB J. 20, 311-313.
26. SCHLESSINGER, J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
27. SEBOLT-LEOPOLD, J.S., and HERRERA, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947.
28. SORDELLA, R., BELL, D.W., HABER, D.A., and SETTLEMAN, J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167.
29. TRACY, S., MUKOHARA, T., HANSEN, M., MEYERSON, M., JOHNSON, B.E., and JANNE, P.A. (2004). Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. Cancer Res. 64, 7241-7244.
30. ULLRICH, A., COUSSENS, L., HAYFLICK, J.S., DULL, T.J., GRAY, A., TAM, A.W., LEE, J., YARDEN, Y., LIBERMANN, T.A., SCHLESSINGER, J., et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425.
31. VELU, T.J., BEGUINOT, L., VASS, W.C., WILLINGHAM, M.C., MERLINO, G.T., PASTAN, I., and LOWY, D.R. (1987). Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238, 1408-1410.
32. WADA, T., QIAN, X.L., and GREENE, M.I. (1990). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61, 1339-1347.
33. YARDEN, Y., and SLIWKOWSKI, M.X. (2001). Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137.